www.G2Gconsulting.com

May 2016

Title	Opportunity No.	Description	Deadline	Funding Level	Eligibility	Link
GENERAL						
U.S. Army Medical Research and Material Command Broad Announcement for Extramural Medical Research (Modification No. 3)	WH81X WH-BAA-12-1	The U.S. Army Medical Research and Materiel Command's (USAMRMC) mission is to provide solutions to medical problems of importance to the American warfighter at home and abroad.	Ongoing	300 awards expected with an estimated total program funding of $600 million	Unrestricted	http://www.grants.gov/search/search.do;jsessionid=rcb3RkBLCx8f3kdClXqQ1yT0qHyhVbJ8T1xqx1gymtNWv8TDWGRM!-337921640?oppId=202913&mode=VIEW
DoD Medical Countermeasure Systems Broad Agency Announcement	MCS-BAA-15-01	This BAA is continuously open and pre-proposals will be evaluated throughout the year. Applications should be based on data from experiments using specific CBRN warfare agents to demonstrate safety, efficacy, or mode of action. DoD is looking for studies on new and better ways to develop MCMs more rapidly and with increased efficiency through enabling technologies, life cycle bioinformatics, and improved logistics tracking.	Ongoing	Awards dependent on need and funding availability	Unrestricted	http://www3.natick.army.mil/docs/JPM%20MCS%20BAA%2015-01.pdf
Research Interests of the Air Force Office of Scientific Research	BAA-AFOSR-2014-0001	AFOSR plans, coordinates, and executes the Air Force Research Laboratory's (AFRL) basic research program in response to technical guidance from AFRL and requirements of the Air Force; fosters, supports, and conducts research within Air Force, university, and industry laboratories; and ensures transition of research results to support U.S. Air Force	This BAA is open until Superseded.	Project determinant. Example: $1M per year.	Small Business	https://www.fbo.gov/index?s=opportunity&mode=form&id=aae3775c2814584ca21f1504e7f3d6a2&tab=core&_cview=1

		needs.				
Biomechanics and Mechanobiology	PD-14-7479	The BMMB Program supports fundamental research in biomechanics and mechanobiology	Jan. 15 – Feb. 15, Annually; Sept. 1 – Oct. 1, Annually	Award Ceiling: $400,000 Award Floor: $5,000	Unrestricted	http://www.nsf.gov/funding/pgm_summ.jsp?pims_id=13523
Cognitive Neuroscience (NSF)	14-514	The Cognitive Neuroscience program seeks highly innovative proposals aimed at advancing a rigorous understanding of how the human brain supports thought, perception, affect, action, social processes, and other aspects of cognition and behavior.	Full Proposal Target Date(s): Feb. 25, Annually	$8,000,000 - annually, pending availability of funds.	Unrestricted	http://www.nsf.gov/publications/pub_summ.jsp?ods_key=nsf14514
Advances in Patient Safety through Simulation Research (R18) (AHRQ, HHS)	PA-14-004	The Agency for Healthcare Research and Quality (AHRQ) is interested in funding a diverse set of projects that develop, test and evaluate various simulation approaches for the purpose of improving the safe delivery of health care.	Jan. 25, May 25, Sept. 25, 2016	36 months in duration with a budget of $250,000 total costs yearly. Multiple projects.	Governments, Public and State controlled institutions of higher education	http://grants.nih.gov/grants/g uide/pa-files/PA-14-004.html
NIH Development and Translation of Medical Technologies to Reduce Health Disparities (SBIR)(R43/R44)	RFA-EB-16-001	This FOA encourages SBIR grant applications from small business concerns that propose to develop and translate medical technologies aimed at reducing disparities in healthcare access and health outcomes. This is a re-issue of Reissue of RFA-EB-15-001 from last Fiscal Year.	July 6, 2016	Expected Number of Awards: 6-10 Est. Total Program Funding: $2,000,000 Ceiling: $200,000 per year for Phase I, $400,000 per year for Phase II	Small Businesses	http://grants.nih.gov/grants/guide/rfa-files/RFA-EB-16-001.html
Platform Delivery Technologies for Nucleic Acid Therapeutics (R41/R42) Platform Delivery Technologies for Nucleic Acid Therapeutics (R43/R44)	PA-14-308 PA-14-307	The purpose of this initiative is to incentivize small businesses to generate new technologies and products for delivering nucleic acids into cells and tissues for the purpose of treatment or prevention of human disease. For the purposes of this FOA, platform technologies are those that are able to deliver nucleic acids to tissues in a sequence-independent manner, and as such are in principle applicable to the treatment of multiple diseases.	Sept. 7, 2016	Budgets up to $325,000 total costs per year for Phase I and up to $2M total costs per year for Phase II may be requested.	Small Businesses	http://grants.nih.gov/grants/guide/pa-files/PA-14-308.html http://grants.nih.gov/grants/guide/pa-files/PA-14-307.html
Developmental Pharmacology and	PAR-13-306	This Funding Opportunity Announcement	Sept. 7, 2016	Grants Notice	Governments, Nonprofits,	http://grants.nih.g

Toxicology: Role of Ontogeny (R01) National Institutes of Health — Department of Health and Human Services		(FOA) encourages grant applications from institutions or organizations that propose multidisciplinary, investigator-initiated basic and translational research in developmental pharmacology and toxicology.			educational institutions, small businesses	ov/grants/guide/pa-files/PAR-13-306.html
Exploratory/Developmental Investigations on Primary Immunodeficiency Diseases (R21)	PA-13-315	The purpose of this Funding Opportunity Announcement (FOA) is to support innovative exploratory/developmental investigations in primary immunodeficiency diseases focusing on ex vivo studies with human specimens and on studies with current or new animal models, including novel clinical strategies for detecting, identifying the molecular basis of, or developing innovative therapies for primary immunodeficiency diseases.	Sept. 7, 2016	Grants Notice	Governments, Nonprofits, educational institutions, small businesses	http://grants.nih.gov/grants/guide/pa-files/PA-13-315.html
Research Centers in Injury and Peri-operative Sciences (P50)	PAR-13-291	The National Institute of General Medical Sciences (NIGMS) encourages grant applications from institutions/organizations for Research Centers in Injury and Peri- operative Sciences (RCIPS).	Sept. 8, 2016	3 awards, corresponding to a total of $8,100,000 for fiscal year 2014	Governments, Nonprofits, educational institutions, small businesses	http://grants.nih.gov/grants/guide/pa-files/PAR-13-291.html
Global "Omics" Approaches Targeting Adverse Pregnancy and Neonatal Outcomes Utilizing Existing Cohorts (R01)	PAR-14-264	"Omics" approaches will be used to delineate the molecular mechanisms as well as to identify new biomarkers that predict adverse pregnancy or neonatal outcomes. The goal of this initiative is to hasten the discovery of the pathophysiology of adverse health pregnancy outcomes, discover novel target molecules and diagnostic biomarkers, and ultimately aid in formulating more effective interventional strategies for their management and prevention. It is anticipated that this initiative will help discoveries concerning major maternal and neonatal health problems by using state of the science technologies by analyzing archived materials from existing, well-characterized cohorts.	Oct. 7, 2016	$500,000 or more, project determinant.	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-14-264.html#_Section_II._Award_1
Bioreactors for Reparative	RFA-HL-15-017	Major obstacles to the	Oct. 14, 2016	$15.975M for a	Small Businesses	http://grants.

Medicine - SBIR Direct Phase II (R44)-NIH		generation of functional tissues and their widespread use are limited by rudimentary tissue growth technologies. The purpose of this funding opportunity is to encourage small businesses to develop sophisticated and complex biomimetic culture systems that are capable of precise control of the cellular and 3-dimensional organ microenvironment, and which address the unique physiological dynamics of heart, lung and blood tissues. Projects awarded under this announcement should show evidence of developing or using good laboratory practice (GLP) standards and/or good manufacturing practices (GMP) standards, which play an important role in the adoption of many technologies used for pre-clinical research. Additionally, sources of cell variability should be discussed in the context of potential elements of measurement assurance and use of reference materials. For projects proposing clinical grade bioreactors and clinical investigations, an applicant must provide evidence that they have contacted the Food and Drug Administration (FDA) for guidance concerning the development of their bioreactor device, such as correspondence regarding investigational new drug (IND) application and status of their project in a timeline related to Federal regulatory approval processes.		total of 19 awards; $750,000 award ceiling		nih.gov/grants/guide/rfa-files/RFA-HL-15-017.html
NSF Chemical and Biological Separations	PD-14-1417	The Chemical and Biological Separations (CBS) program supports fundamental research on novel methods and materials for separation processes.	Oct. 17, 2016	Total funding $3,200,000; Award Floor $300,000	Unrestricted	http://www.nsf.gov/funding/pgm_summ.jsp?pims_id=13363
Collaborative Projects to Accelerate Research in Organ Fibrosis (R01)	RFA-HL-16-003	While fibrogenesis is an essential process in normal wound healing, aberrant and relentless fibrogenesis in vital	Oct. 21, 2016	Award ceiling: $350,000	Unrestricted	http://grants.nih.gov/grants/guide/rfa-files/RFA-HL-

		organs such as heart, lung, kidney, and bone marrow can lead to debilitating symptoms and organ failure. Aberrant fibrogenesis at the cellular level shows remarkable similarities across different organ systems. Moreover, a disease such as systemic sclerosis or an injury such as ionizing radiation may cause fibrosis in more than one organ system. Thus, collaborations among researchers studying fibrosis in different organ systems may greatly accelerate research in this area. This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications from collaborating investigators to characterize and compare mechanisms of aberrant fibrogenesis and/or fibrosis resolution in different organ systems; develop novel therapeutic strategies aimed to lessen organ fibrosis; or develop novel technologies to study fibrosis.				16-003.html
Oral HIVacc: Oral Mucosal Immunization Approaches for HIV Prevention (R01)(NIH)	RFA-DE-16-006	FOA seeks research projects to: 1) define the mechanisms by which direct HIV vaccination of oral lymphoid tissues induce oral innate as well as local and systemic adaptive immune responses; 2) determine the mechanisms by which new adjuvants used together with oral HIV vaccine candidates enhance local and systemic immunity; 3) test innovative, oral vaccine vectors expressing HIV vaccine antigens to trigger protective immunity; 4) compare different HIV vaccine immunization strategies and schemes for the oral mucosa to maximize protection; and 5) delineate the role of dynamic changes in oral and immune cell subsets and their interactions to enhance immunity upon oral HIV vaccination.	Nov. 23, 2016	Est. Total Program Funding: $2,000,000	Unrestricted	http://grants.nih.gov/grants/guide/rfa-files/RFA-DE-16-006.html
The Role of the Human	RFA-HL-17-002	The human virome includes	Dec. 9, 2016	Number of	Unrestricted	http://grants.

Virome in Heart, Lung, and Blood Health and Resilience (R61/R33)		viruses that infect host cells, virus-derived elements in our chromosomes, and viruses that infect other types of organisms that inhabit the human body. The virome may influence the host in profound ways independent of classical viral diseases. The purpose of this opportunity is to support research to identify and evaluate the basic underlying molecular and physiological mechanisms by which the virome may influence heart, lung, and blood (HLB) health and resilience.		Awards contingent upon NIH appropriations		nih.gov/grants/guide/rfa-files/RFA-HL-17-002.html#_Section_II._Award_1
Direct Phase II SBIR Grants to Support Biomedical Technology Development	PAR-14-088	The purpose of this funding opportunity announcement (FOA) is to encourage applications to the newly authorized Direct-to- Phase II SBIR grant mechanism.	Jan. 7, 2017	Project determinate.	Small businesses	http://grants.nih.gov/grants/ guide/pa-files/PAR-14-088.html
Targeted Basic Behavioral and Social Science and Intervention Development for HIV Prevention and Care (R01) and (R21) Series of HIV related Grants.	PA-14-127 PA-14-128 PA-14-129 PA-14-131 PA-14-126 PA-14-130 PA-14-125 PA-14-133 PA-14-134 PA-14-132	The goal of this funding opportunity announcement (FOA) is to provide a global outline of areas for innovative, targeted basic behavioral and social science research and intervention development research to reduce the number of new HIV infections and improve the overall health of those living with HIV and encourage research grant applications in these areas.	Jan. 7, 2017	Project determinant.	Varies	http://www.oar.nih.gov/
Role of the Microbiome in HIV-1 Vaccine Responses (R21) Role of the Microbiome in HIV-1 Vaccine Responses (R01)	PAR-14-318 PAR-14-317	Grant funding is to stimulate research focused on elucidating the role of the microbiome in shaping the host immune responses to HIV-1 transmission and vaccination in the gastrointestinal and genital mucosa. By understanding the positive and negative interactions of the microbiome and its relationship to host immune function, it is expected that the proposed research will lead to the development of innovative approaches to enhance mucosal and systemic responses to HIV vaccines and in the development of new vaccine strategies. The R21	Jan. 7, 2017	R21: Award Ceiling: $275,000 R01: Budgets not limited but need to reflect the needs of the proposed project.	Unrestricted	http://www.grants.gov/web/grants/view-opportunity.html?oppId=261572 https://grants.nih.gov/grants/guide/pa-files/PAR-14-317.html

		mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects.				
Genomic Resource Grants for Community Resource Projects (U41)	PAR-14-191	Genomic research has had substantial impact on biomedical research, in large part because of the open sharing of data and resources with the greater research community.	Jan. 25, 2017	Not currently listed.	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-14-191.html
Predictive Multiscale Models for Biomedical, Biological, Behavioral, Environmental and Clinical Research (U01)	PAR-15-085	The goal of this interagency funding opportunity announcement (FOA) is to support the development of multiscale models to accelerate biological, biomedical, behavioral, environmental and clinical research. The NIH, ARO, DOE, FDA, NASA, NSF, and ONR recognize that in order to efficiently and effectively address the challenges of understanding multiscale biological and behavioral systems, researchers will need predictive, computational models that encompass multiple biological and behavioral scales. This FOA supports the development of non-standard modeling methods and experimental approaches to facilitate multiscale modeling, and active participation in community-driven activities through the Multiscale Modeling (MSM) Consortium.	Jan. 29, 2017	N/A	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-15-085.html
Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01)	PAR-14-166	This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools.	Feb. 9, 2017	$250,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-14-166.html

Direct Phase II SBIR Grants to Support Extended Development, Hardening, and Dissemination of Technologies in Biomedical Computing, Informatics, and Big Data Science (R44)	PAR-15-288	This FOA encourages SBIR grant applications from small business concerns (SBCs) that propose the extended development, maintenance, testing, evaluation, hardening and dissemination of existing biomedical software. This FOA is for applications that have completed the proof of concept Phase I stage-type of research through other (non-SBIR) funding sources. The NIH is interested in promoting a broad base of research and development of a broad base of innovative technologies in biomedical computing, informatics, and Big Data Science that will support rapid progress in areas of scientific opportunity in biomedical research. It is expected that this research and development is conducted in the context of important biomedical and behavioral research problems. As such, applications are intended to develop enabling technologies that could apply to the interests of most NIH Institutes and Centers and range from basic biomedicine to research in all relevant organ systems and diseases.	April 5,2017	Total funding support normally may not exceed $1,000,000 for Phase II awards	Small businesses	http://grants.nih.gov/grants/guide/pa-files/PAR-15-288.html
NIBIB Quantum Program: Technological Innovation to Solve a Major Medical or Public Health Challenge (U01)	PAR-15-031	The goal of the National Institute of Biomedical Imaging and Bioengineering (NIBIB) Quantum Program is to achieve a profound (quantum) advance over present-day approaches to the prevention, detection, diagnosis, and/or treatment of a major disease or national public health problem primarily through the development of biomedical engineering/biomedical imaging technologies. In order to realize a profound advance against a major disease or national public health problem, this announcement supports research to develop and prepare a target technology for clinical efficacy at the completion of Quantum	May 7, 2017	N/A	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-15-031.html

		funding				
Alcohol-Induced Effects on Tissue Injury and Repair (R21) and (R01)	PA-14-124	Encourages Exploratory/Developmental Research Grant Award (R21) applications to study molecular and cellular mechanisms of tissue injury and repair associated with alcohol use in humans.	May 7, 2017	$200,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-14-124.html
NEI Clinical Vision Research: Resource Center Grant (UG1); Chairman's Grant; Clinical Center Grant; Coordinating Center Grant; Research Project Grant	PAR-14-096 PAR-14-097 PAR-14-098 PAR-14-099 PAR-14-100	The National Eye Institute (NEI) supports investigator-initiated clinical vision research projects, including multi-center clinical trials and other complex or high-risk clinical vision research studies.	May 7, 2017	Not currently listed.	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-14-096.html
Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science (R43/R44) SBIR	PA-14-154	See attached link.	May 7, 2017	$150,000 for Phase I awards and $1,000,000 for Phase II awards.	Small Businesses	http://grants.nih.gov/grants/guide/pa-files/PA-14-154.html#_Section_II._Award_1
Early Stage Development of Technologies in Biomedical Computing, Informatics, and Big Data Science (R41/R42) STTR	PA-14-157	See attached link.	May 7, 2017	$150,000 for Phase I awards and $1,000,000 for Phase II awards.	Small Businesses	http://grants.nih.gov/grants/guide/pa-files/PA-14-157.html
Community Partnerships to Advance Research (CPAR) (R21) (R01) (R15)	PA-14-140 PA-14-141 PA-14-142	This funding opportunity announcement addresses the need for researchers to partner with communities using Community Engaged Research (CEnR) methodologies that will enhance relationships leading to better interventions and positive health outcomes.	May 7, 2017	Ceiling: $200,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-14-141.html#_Section_II._Award_1
mHealth Tools for Underserved Populations with Chronic Conditions to Promote Effective Patient-Provider Communication, Adherence to Treatment and Self- Management	PA-14-181 PA-14-180	The purpose of this initiative is to stimulate research utilizing Mobile Health (mHealth) tools aimed at the improvement of effective patientprovider communication, adherence to treatment and self-management of chronic	May 7, 2017	$200,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-14-181.html

(R21), (R01)		diseases in underserved populations.				
Discovery of in vivo Chemical Probes (R01)-NIH	PAR-14-279	This Funding Opportunity Announcement (FOA) intends to support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes. It is expected that applicants will have in hand the starting compounds (validated hits) for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes, and 2) discovery and/or validation of novel, biological targets that will inform studies of disease mechanisms. Emphasis will 2be placed on projects that provide new insight into important disease targets and processes.	Sept. 6, 2017	Not limited	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-14-279.html
High Throughput Screening (HTS) to Discover Chemical Probes (R21)-NIH	PAR-14-283	This Funding Opportunity Announcement (FOA) encourages investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatments relevant to the missions of the participating NIH Institutes, and 2) discovery and/or validation of novel, biological targets that will inform studies of disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease	Sept. 6, 2017	Total direct costs limited to $275,000 over an R21 two-year period; no more than $200,000 in direct costs in any single year	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-14-283.html

		targets and processes.				
High Throughput Screening (HTS) to Discover Chemical Probes (R01)-NIH	PAR-14-284	This Funding Opportunity Announcement (FOA) encourages investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatments relevant to the missions of the participating NIH Institutes, and 2) discovery and/or validation of novel, biological targets that will inform studies of disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease targets and processes.	Sept. 6, 2017	Not limited	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-14-284.html
NIDCR Clinical Trial or Biomarker Clinical Validation Study Planning Grant (R34)	PAR-14-346	This Funding Opportunity will support activities to develop: the draft clinical protocol; the Clinical Investigators Brochure (or equivalent) if needed; tools for data and quality management, safety and operational oversight plans; recruitment and retention strategies; the study team; and other essential documents such as a draft Manual of Procedures that are necessary for the subsequent clinical trial or biomarker clinical validation study.	Sept. 7, 2017	Award ceiling: $150,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-14-346.html
Biology of the Temporomandibular Joint in Health and Disease (R21)	PA-14-359	The purpose of this FOA is to encourage research that will advance our understanding of the temporomandibular joint (TMJ) in health and disease and to stimulate research that complements previous efforts and focuses on the biology of joint function and the tissues that make up the TMJ. A better understanding of total joint structure and mechanics	Sept. 7, 2017	Award ceiling: $275,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-14-359.html

Biology of the Temporomandibular Joint in Health and Disease (R01)	PA-14-358	including the interactions of the skeletal, muscular, nervous, immune, and circulatory systems using new in vivo and in vitro models is needed. An expected outcome of this FOA is new knowledge that will provide a basis for developing novel approaches to prevent, diagnose, assess risk, and treat temporomandibular joint disorder (TMD).	Sept. 7, 2017			http://grants.nih.gov/grants/guide/pa-files/PA-14-358.html
Research on Chronic Overlapping Pain Conditions (R21)	PA-14-243	The purpose of this FOA is to encourage epidemiological, clinical and translational research that will increase our understanding of the natural history, prevalence, biological mechanisms, psychological variables, and clinical risk factors responsible for the presence of multiple chronic pain conditions in people with pain. Recent clinical findings suggest that substantial overlap may exist between chronic pain conditions. Individuals diagnosed with one disorder often exhibit characteristics of additional chronic painful conditions or transition to other diagnostic categories. A better understanding is needed of the prevalence of overlapping pain conditions, the underlying etiologies, the progression of these conditions, the evolution of these overlaps, and the therapeutic approaches best suited for treating subjects with these conditions.	Sept. 7, 2017	$200,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-14-243.html
High Throughput Screening (HTS) to Discover Chemical Probes (R21)-NIH	PAR-14-283	This Funding Opportunity Announcement (FOA) encourages investigators to form collaborations with an established academic, nonprofit, or commercial high throughput screening (HTS) facility that has the requisite expertise and experience to implement HTS-ready assays for the discovery and development of small molecule chemical probes. Through this FOA, NIH wishes to stimulate research in 1) discovery and	Sept. 7, 2017	$200,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-14-283.html

		development of novel, small molecules for their potential use in studying disease treatments relevant to the missions of the participating NIH Institutes, and 2) discovery and/or validation of novel, biological targets that will inform studies of disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease targets and processes.				
Developing Interventions for Health-Enhancing Physical Activity (R21/R33)	PAR-14-321	This FOA encourages innovative research to improve our understanding of how to increase and maintain health-enhancing physical activity to make meaningful and lasting change, with an emphasis on multi-level interventions that have the potential to be scalable, implementable, and sustained in real-world settings. Interventions to be tested should seek to increase participants' progression toward achieving the 2008 Physical Activity Guidelines for Americans as appropriate to the participants' health, abilities, and conditions.	Sept. 9, 2017	R21 not to exceed $325,000 R33 phase may not exceed $525,000 in direct costs for the 3-year project period, with no more than $250,000 in direct costs in any single year of the R33 phase.	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-14-321.html
Testing Interventions for Health-Enhancing Physical Activity (R01)	PAR-14-315	Purpose of this Funding Opportunity Announcement (FOA) is to fund highly innovative and promising research that tests multi-level intervention programs of 1 to 2 years in length that are designed to increase health-enhancing physical activity: 1) in persons or groups that can benefit from such activity; and 2) that could be made scalable and sustainable for broad use across the nation. This FOA provides support for up to 5 years for research planning, intervention delivery, and follow-up activities.	Sept. 9, 2017	Number of awards contingent upon NIH appropriations and submission of a sufficient number of meritorious applications. Budgets not limited but need to reflect the needs of the proposed project.	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-14-315.html
Patient Safety in the Context of Perinatal, Neonatal, and Pediatric Care (R03) Patient Safety in the	PA-14-313	This funding initiative encourages a wide range of collaborative research projects related to patient safety in the context of perinatal, neonatal and pediatric care both in routine hospital settings and in the intensive care units. The	Sept. 9, 2017	Award Ceiling: $50,000	Unrestricted	http://www.grants.gov/web/grants/view-opportunity.html?oppId=261183

Context of Perinatal, Neonatal, and Pediatric Care (R21)	PA-14-311	FOA welcomes applications related to (but not limited to): the epidemiology of various domains of medical errors and consequent patient harm; assessing the factors at various levels that contribute to such errors; and intervention strategies at individual, systems, and institutional levels to help reduce and eliminate medical errors. It is anticipated that knowledge gained from these projects will help develop strategies to deliver highest quality of healthcare to all newborn infants and children with utmost safety and effectiveness.				
Resource Program Grants in Bioinformatics (P41)	PAR-14-357	Invites applications for Resource Program Grants in Bioinformatics for supporting the continued operation, improvement, and dissemination of databases, digital information, or software tools that are unique, and of special importance to research using animal models of embryonic developmental processes.	Sept. 25, 2017	Award ceiling: $1,750,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-14-357.html
Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01)	PAR-15-115	This Funding Opportunity Announcement (FOA) is to encourage Research Project Grant (R01) applications to pursue clinical observational (CO) studies to obtain data necessary for designing clinical trials for musculoskeletal, rheumatic, or skin diseases or conditions. Research data from observational cohort studies can enhance clinical trial design by providing essential information about disease symptoms, stages and timing of disease progression, comorbid conditions, availability of potential clinical trial participants, and outcomes that are important to patients. CO studies also can facilitate efforts to develop and/or validate objective biomarkers or subjective outcome measures for use in a future trial or trials.	Nov. 1, 2017	Award Ceiling: $225,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-15-115.html

NeuroNEXT Infrastructure Resource Access (X01) NeuroNEXT Small Business Innovation in Clinical Trials Direct to Phase II (U44)	PAR-15-195 PAR-15-194	This FOA encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests. This Funding Opportunity Announcement (FOA) encourages small business applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required for designing clinical studies. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests (www.ninds.nih.gov/funding/areas/index.htm).	Nov. 12, 2017 Dec. 12, 2016	N/A	Unrestricted Small Businesses	http://grants.nih.gov/grants/guide/pa-files/PAR-15-195.html http://grants.nih.gov/grants/guide/pa-files/PAR-15-194.html
Air Force Research Laboratory, AFRL/RX, Materials & Manufacturing Directorate BAA	BAA-RQKM-2013-0005	The objective of the AFRL Research Collaboration program is to enable collaborative research partnerships between AFRL and Academia and Industry.	Dec. 20, 2017	Estimated Total Program Funding: $49.5 million (40 awards expected at $100-$750,000)	Unrestricted	http://www.grants.gov/search/search.do;jsessionid=rcb3RkBLCx8f3kdClXqQ1yT0qHyhVbJ8T1xqx1gymtNWv8TDWGRM!-337921640?oppId=106033&mode=VIEW
Development of Novel and Emerging Technologies to Support Zebrafish Models for Biomedical Research (R41/R42) Development of Novel	PA-15-087	There is a need to develop technologies that support research using zebrafish models of biomedical value. The zebrafish has become increasingly important as a biological resource, because of its small size, short generation time, easy manipulation of	Jan. 7, 2018	N/A	Small Businesses	http://grants.nih.gov/grants/guide/pa-files/PA-15-087.html

and Emerging Technologies to Support Zebrafish Models for Biomedical Research (R43/R44)	PA-15-086	embryos and optical transparency. This animal model is used to study aspects of gene structure and function that can be directly related to human genetics and disease. Zebrafish are also important for studies in diverse disciplines, including pharmacology, toxicology, neurobiology, behavior and developmental biology				http://grants.nih.gov/grants/guide/pa-files/PA-15-086.html
Radiological/Nuclear Medical Countermeasure Product Development Program (R43/R44)	PA-15-065	The purpose of this Funding Opportunity Announcement (FOA) is to encourage new or renewal Small Business Innovation Research (SBIR) grant applications focused on specific product development activities for radiological/nuclear medical countermeasures leading to Investigational New Drug (IND) or Investigational Device Exemption (IDE) submission packages to the U.S. Food and Drug Administration.	Jan. 7, 2018	N/A	Small Businesses	http://grants.nih.gov/grants/guide/pa-files/PA-15-065.html
Unconventional Roles of Ethanol Metabolizing Enzymes, Metabolites, and Cofactors in Health and Disease (R01) Unconventional Roles of Ethanol Metabolizing Enzymes, Metabolites, and Cofactors in Health and Disease (R21)	PA-15-058 PA-15-057	The purpose of this FOA is to provide support for integrated, innovative research on the novel and unconventional contributions of ethanol metabolizing pathways, their metabolites, cofactors, and interactions with synergizing biological pathways in the development of alcohol-induced diseases and end organ injuries. It is anticipated that research supported under this FOA will generate data that leads to breakthroughs in identification and understanding of key cellular and molecular components in the initiation, progression and maintenance of the diverse medical disorders caused by excessive or long term alcohol consumption.	Jan. 7, 2018 Jan. 7, 2018	N/A Award Ceiling: $275,000	Unrestricted Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-15-058.html http://grants.nih.gov/grants/guide/pa-files/PA-15-057.html
Advancing Interventions to Improve Medication Adherence (R01)	PA-14-334	This FOA seeks Research Project Grant (R01) applications that propose interventions to significantly improve medication adherence	Jan. 7, 2018	N/A	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-14-334.html

Advancing Interventions to Improve Medication Adherence (R21)	PA-14-335	in individuals. Applications may target medication adherence in the context of treatment for a single illness or chronic condition (e.g., hypertension), to stave off a disease recurrence (e.g., cancer) or for multiple comorbid conditions (e.g., hypertension, diabetes, alcohol use disorders and HIV/AIDS).	Jan. 7, 2018	Award ceiling: $275,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-14-335.html
Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R01) Biobehavioral and Technological Interventions to Attenuate Cognitive Decline in Individuals with Cognitive Impairment or Dementia (R21)	PA-15-017 PA-15-015	The purpose of this funding opportunity announcement (FOA) is to stimulate clinical research focused on biobehavioral or technological interventions to attenuate cognitive decline in individuals with dementia (such as Alzheimers disease, Lewy body dementia, vascular dementia), mild cognitive impairment (MCI), or disease- or age-related cognitive decline.	Jan. 7, 2018 Jan. 7, 2018	N/A Award Ceiling: $275,000	Unrestricted Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-15-017.html http://grants.nih.gov/grants/guide/pa-files/PA-15-015.html
Studies in Neonatal and Pediatric Resuscitation (R03)	PA-14-351	Encourages a wide range of collaborative research projects related to patient safety in the context of perinatal, neonatal and pediatric care both in routine hospital settings and in the intensive care units. Welcomes applications related to (but not limited to): the epidemiology of various domains of medical errors and consequent patient harm; assessing the factors at various levels that contribute to such errors; and intervention strategies at individual, systems, and institutional-levels to help reduce and eliminate medical errors. It is	Jan. 7, 2018	Award Ceiling: $50,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-14-351.html

		anticipated that knowledge gained from these projects will help develop strategies to deliver highest quality of healthcare to all newborn infants and children with utmost safety and effectiveness.				
NIH: Lab to Marketplace: Tools for Biomedical and Behavioral Research (R43/R44)	PA-15-052	This Funding Opportunity Announcement (FOA) encourages the translation of technologies for biomedical or behavioral research from academic and other non-small business research sectors to the marketplace. Small Business Concerns (SBCs) are encouraged to submit Small Business Innovation Research (SBIR) grant applications that propose to further develop, make more robust, and make more user-friendly such technologies in preparation for commercial dissemination. It is expected that this activity will require partnership and close collaboration between the original developers of these technologies and applicant SBCs, which may be accomplished in any of a number of ways, including the use of multiple principal investigators.	Jan. 7, 2018	N/A	Small Businesses	http://grants.nih.gov/grants/guide/pa-files/PA-15-052.html
Novel Biomarkers for the Development of HIV Incidence Assays with Improved Specificity (R01)	PA-15-105	This Funding Opportunity Announcement (FOA) invites Research Project Grant (R01) applications to support the development of novel biomarkers and improved HIV incidence assays and algorithms with increased specificity for distinguishing incident from chronic HIV infections.	Jan. 7, 2018	N/A	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-15-105.html
NIH Mentored Clinical Scientist Research Career Development Award (Parent K08)	PA-16-191	The objective of this FOA is to provide salary and research support for a sustained period of "protected time" (3-5 years) to support didactic study and/or mentored research for individuals with clinical doctoral degrees (e.g., MD, DDS, DMD, DO, DC, OD, ND,	Jan. 7, 2018	Contingent upon NIH funding	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-16-191.html#_Section_II._Award_2

		DVM, PharmD, or PhD in clinical disciplines). The K08 provides support for an intensive, mentored research career development experience in biomedical or behavioral research, including translational research.				
NIH Mentored Patient-Oriented Research Career Development Award (Parent K23)	PA-16-198	The objective of this FOA is to provide salary and research support for 3-5 years to ensure a future cadre of well-trained scientists conducting NIH-supported Patient-Oriented Research (POR). For the purposes of the K23 award, Patient-Oriented Research is defined as research conducted with human subjects (or on material of human origin such as tissues, specimens and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects.	Jan. 7, 2018	Contingent upon NIH funding	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-16-198.html
NIH Independent Scientist Award (Parent K02)	PA-16-192	The award is intended to foster development of outstanding scientists and enable them to expand their potential to make significant contributions to their field of research. It provides three, four, or five years of salary support and "protected time" for newly independent scientists who can demonstrate the need for a period of intensive research focus as a means of enhancing their research careers.	Jan. 7, 2018	Contingent upon NIH funding	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-16-192.html
Characterization of Mycobacterial Induced Immunity in HIV-infected and Uninfected Individuals (R21)	PAR-15-360	Purpose is to support hypothesis-generating research on innate and adaptive immune responses induced by mycobacterial infection, Bacillus Calmette-Gurin vaccine (BCG), or other Mycobacterium tuberculosis (Mtb) vaccinations. Studies that include evaluation of immune responses by anatomical location in HIV-infected or uninfected individuals are of particular interest.A secondary objective of this FOA is development of	Jan. 11, 2018	Award Ceiling: $200,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-15-360.html

		new assays and technologies enabling comparison of mycobacterial-specific mucosal and systemic immunological pathways in HIV-infected or uninfected individuals that can be used to monitor immune responses in preclinical studies and vaccine trials to advance Mtb vaccine development.				
Bioengineering Research Partnership (BRP): Non- or Minimally-Invasive Methods to Measure Biochemical Substances during Neonatal and Perinatal Patient Care and Research (R01)(NIH)		The goal for a Bioengineering Research Partnership (BRP) is to drive the development and speed the adoption of promising tools and technologies that can address important biomedical research problems for which there is a scarcity of solutions. The use of engineering principles is encouraged to establish these tools and technologies as robust, well-characterized solutions that fulfill an unmet need. A synergistic partnership between the engineering, and biomedical professions is required, where the unique skills of each discipline combine to enhance our understanding of life science processes or the practice of medicine.	Jan. 17, 2018	Collaboration Opportunity	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-15-285.html
United States Army Research Institute for the Behavioral and Social Sciences BAA for Basic, Applied, and Advanced Scientific Research (FY13-18)	W911NF-13-R-0001	Programs funded under this BAA include basic research, applied research, and advanced technology development that can improve human performance and Army readiness.	Feb. 5, 2018	N/A	Unrestricted	http://www.grants.gov/search/search.do;jsessionid=rcb3RkBLCx8f3kdClXqQ1yT0qHyhVbJ8T1xqx1gymtNWv8TDWGR M!-337921640?oppId=219293&mode=VIEW
NINDS Exploratory Clinical Trials for Small Business (R42)	PAR-15-278	The purpose of this funding opportunity announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Technology Transfer (STTR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of	April 5, 2018	Total Funding Support may Not Exceed: $150,000 for Phase I; $1,000,000 for Phase II	Small Businesses	http://grants.nih.gov/grants/guide/pa-files/PAR-15-278.html

NINDS Exploratory Clinical Trials for Small Business (R44)	PAR-15-277	Neurological Disorders and Stroke (NINDS). The projects must focus on products related to the mission and goals of the NINDS and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Only STTR Phase II and Fast-Track applications are supported under this program. STTR Phase I applications are only accepted as part of a Fast-track application. The purpose of this funding opportunity announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Neurological Disorders and Stroke (NINDS). The projects must focus on products related to the mission and goals of the NINDS and may evaluate drugs, biologics, devices, or diagnostics, as well as surgical, behavioral or rehabilitation therapies. Only SBIR Phase II and Fast-Track applications are supported under this program. SBIR Phase I applications are only accepted as part of a Fast-track application.	April 5, 2018	Total Funding Support may Not Exceed: $150,000 for Phase I; $1,000,000 for Phase II	Small Businesses	http://grants.nih.gov/grants/guide/pa-files/PAR-15-277.html
Advancing Mechanistic Probiotic/Prebiotic and Human Microbiome Research (R01) (NIH)	PA-15-135	The purpose of this FOA is: (1) to stimulate basic and mechanistic science that facilitates the development of effective probiotics or pre-/probiotic combinations of relevance to human health and disease; and (2) determine biological outcomes for the evaluation of efficacy of pre/probiotics in appropriate test systems and animal models. This FOA encourages basic and mechanistic studies using in vitro, in vivo, ex vivo, and in silico models that focus	May 7, 2018	No limit specified	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-15-135.html

		on prebiotic/probiotic strain selectivity, interaction, and function. It will also encourage inter and multidisciplinary collaborations among scientists in a wide range of disciplines including nutritional science, immunology, microbiomics, genomics, other '-omic' sciences, biotechnology, and bioinformatics.				
Pilot Clinical Trials for the Spectrum of Alzheimers Disease and Age-related Cognitive Decline (R01) Phase III Clinical Trials for the Spectrum of Alzheimer's Disease and Age-related Cognitive Decline (R01)	PAR-16-365 PAR-16-364	Invites applications that propose to develop and implement Phase I or II clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and in individuals with Alzheimer's disease (AD). Encourages R01 grant applications that propose to develop and implement Phase III clinical trials of promising pharmacological and non-pharmacological interventions in individuals with age-related cognitive decline and across the Alzheimer's disease (AD) spectrum from pre-symptomatic to more severe stages of disease.	Mar. 7, 2018	Est. Total Program Funding: $10,000,000 Est. Total Program Funding: $25,000,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PAR-16-365.html http://grants.nih.gov/grants/guide/pa-files/PAR-16-364.html
Clinical Studies of Safety and Effectiveness of Orphan Products Research Project Grant (R01)	RFA-FD-15-001	The goal of FDA's OPD grant program is to support the clinical development of products for use in rare diseases or conditions where no current therapy exists or where the product being developed will be superior to the existing therapy. FDA provides grants for clinical studies on safety and/or effectiveness that will either result in, or substantially contribute to, market approval of these products. =	Oct. 18, 2018	Est. Total Program Funding: $14,100,000 Award Ceiling: $500,000 Award Floor: $250,000	Unrestricted	http://grants.nih.gov/grants/guide/rfa-files/RFA-FD-15-001.html
HUMAN PERFORM-ANCE SENSING	BAA-RQKHB-2015-0003	This BAA employs the Sense-Assess-Augment paradigm to accelerate research and development of technologies capable of detecting/assessing human performance. This BAA focuses on identifying,	Oct. 29, 2018	Est. Total Program Funding: $39,800,000 Award Ceiling: $2,000,000	Unrestricted	https://www.fbo.gov/index?s=opportunity&mode=form&id=6dccb53be3d0794eb70559b25ea9

		developing, characterizing, and accelerating sensing technologies that can be utilized to assess the physiological, cognitive, and psychological states of human operators. It is also anticipated that these technologies will be implemented into fieldable systems. Research will have an emphasis on developing technologies capable of detecting & sensing physiological, biomarker, and behavioral metrics which are or can be correlated with human state/performance.		Award Floor: $150,000 Expected Number of Awards: 8		d074&tab=core&_cview=1
NIH Development of Animal Models and Related Biological Materials for Research (R21)	PA-16-141	This FOA encourages highly innovative research to develop, characterize or improve animal models and related biological materials for human health and disease or to improve diagnosis and control of diseases that might interfere with animal use for biomedical research.	May 7, 2019	Award Ceiling: $275,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-16-141.html#_Section_I._Funding
NIH Exploratory/ Developmental Research Grant Program (Parent R21)	PA-16-161	This parent grant opportunity encourages applicants to identify and approach participating NIH Institutes and Centers whose missions support their research projects. This opportunity is for exploratory research, distinct from R01 opportunities.	May 7, 2019	Award Ceiling: $275,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-16-161.html
NIH Small Research Grant Program (Parent R03)	PA-16-162	This parent FOA supports discrete, well-defined projects that realistically can be completed in two years and that require limited levels of funding.	May 7, 2019	Award Ceiling: $50,000	Unrestricted	http://grants.nih.gov/grants/guide/pa-files/PA-16-162.html#_Section_I._Funding